SCHEMBL4846420

SCHEMBL4846420

Nc1ccc2cccc-2o1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
TSHR P16473 2/20 0.42
TAAR1 Q96RJ0 3/20 0.41
NQO2 P16083 3/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2E1 P05181 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2A6 P11509 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2B6 P20813 1/20 0.39
CYP2C19 P33261 1/20 0.39
RAB9A P51151 3/20 0.38
NPC1 O15118 2/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
MITF O75030 1/20 0.37
HPGD P15428 2/20 0.36
TOP2A P11388 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26365065 0.85 CYP3A4 (0.54) ALDH1A1TAAR1NQO2CYP3A4CYP2E1
SCHEMBL28212589 0.76 ALDH1A1 (0.52) ALDH1A1NQO2RAB9ANPC1MEN1
Hydrochloric Acid SCHEMBL27880884 0.75 ALDH1A1 (0.47) ALDH1A1RAB9ANPC1MEN1KMT2A
SCHEMBL27883787 0.70 TDP1 (0.48) ALDH1A1TSHRNQO2RAB9ANPC1
SCHEMBL27741062 0.70 ALDH1A1 (0.52) ALDH1A1TSHRNQO2CYP3A4CYP2E1
SCHEMBL12477624 0.70 ALDH1A1 (0.42) ALDH1A1TSHRNQO2CYP3A4CYP2E1
SCHEMBL27736349 0.70 ALDH1A1 (0.42) ALDH1A1TSHRNQO2CYP3A4CYP2E1
SCHEMBL27149030 0.70 EGFR (0.46) ALDH1A1CYP3A4KDM4EMITFHPGD
SCHEMBL12230560 0.68 HSD17B10 (0.64) ALDH1A1TSHRTAAR1NQO2CYP3A4
SCHEMBL2889732 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442705-B2 HIV replication inhibiting pyrimidines and triazines TIBOTEC PHARMACEUTICALS LTD (IE) 2008-10-28 US disclosed
EP-1597238-B1 HIV REPLICATION INHIBITING PYRIMIDINES AND TRIAZINES TIBOTEC PHARM LTD (IE) 2007-05-09 EP disclosed
US-20060194804-A1 Hiv replication inhibiting pyrimidines and triazines TIBOTEC BVBA 2006-08-31 US disclosed
EP-1597238-A1 HIV REPLICATION INHIBITING PYRIMIDINES AND TRIAZINES Tibotec Pharmaceuticals Ltd. (IE) 2005-11-23 EP disclosed
WO-2004074262-A1 HIV REPLICATION INHIBITING PYRIMIDINES AND TRIAZINES TIBOTEC PHARMACEUTICALS LTD. (IE) 2004-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194804-A1 Hiv replication inhibiting pyrimidines and triazines TYMS, UMPS, DUT ALDH1A1 2723/4885TSHR 4623/4885TAAR1 3302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.